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Executive Summary 2015 
 
The annual publication of the Integrated HIV/AIDS, STD, and Viral Hepatitis Surveillance 
Report provides data on the diseases reported to the Bureau of Infectious Disease and Laboratory 
Sciences by healthcare providers and laboratories per regulation (105 CMR 300.000). This report 
focuses on a subset of these diseases:  
 Chlamydia 
 Gonorrhea 
 Hepatitis B 
 Hepatitis C 
 HIV/AIDS 
 Syphilis 
The intended audience for this annual surveillance report includes the clinicians and the 
laboratory professionals who report cases, as well as the community organizations, local public 
health departments, advocates, policymakers, and researchers who are interested in the health of 
Massachusetts residents. 
 
Key highlights in 2015  
 
Chlamydia, gonorrhea, and syphilis: 
 Chlamydia continues to be the most commonly reported infectious disease, with 
approximately 24,000 cases reported annually since 2012. 
 Gonorrhea is now clearly disproportionately reported in men among whom rates have 
doubled over the last decade.  
 The incidence rate of infectious syphilis (primary, secondary, and early latent 
syphilis) has increased 31% to a ten year high of 11.7 per 100,000 in 2015.  Syphilis 
continues to disproportionally affect men, reflecting the ongoing syphilis epidemic in 
men who have sex with men. 
 Young adults have the highest rates of chlamydia, gonorrhea, and syphilis, compared 
to other age groups. 
 
HIV/AIDS:
1
 
 The number of HIV infection diagnoses decreased by 31% from 2005 (N=913) to 
2014 (N=629). Due to improved survival and lower rates of death, the number of 
persons known to be living with HIV/AIDS in Massachusetts increased 26% between 
2005 (N=15,666) and 2014 (N=19,747). 
 Black (non-Hispanic) and Hispanic/Latino residents had significantly higher rates of 
HIV infection diagnoses compared to white (non-Hispanic) residents. This was most 
notable in women, as 78% of women newly diagnosed between 2012 and 2014 were 
black (non-Hispanic) or Hispanic/Latina. 
                                                 
1
 Due to the extensive follow up required to verify date of diagnosis, all HIV/AIDS data reflect HIV infection 
diagnosed through 2014. 
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 Male-to-male sex remained the single most frequently reported exposure mode 
among newly diagnosed cases of HIV infection, and represented 61% of newly 
diagnosed cases among men during 2012 to 2014. 
 
Hepatitis B and C: 
 Reported confirmed cases of chronic hepatitis B continued to decline, due in large 
part to near-universal immunization of children in the United States.  
 An average of over 8,500 confirmed and probable hepatitis C cases were reported in 
each of the past nine years (2007 to 2015).  
 There continued to be an increase of hepatitis C cases reported among adolescents 
and young adults, reflecting ongoing transmission among young people injecting 
opioids. 
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CHLAMYDIA 
 
 
 
 23,913 cases of chlamydia were reported in Massachusetts in 2015 - making it the most 
frequently reported infection in the Commonwealth.    
 The total number of reported chlamydia cases increased by 57% from 15,268 in 2006 to 
23,913 in 2015. 
 In 2015, the chlamydia incidence rate among women (442.9 per 100,000) was nearly 
twice as high as the rate among men (255.5 per 100,000). 
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 The five jurisdictions with the highest chlamydia incidence rates were Provincetown, 
Lawrence, Springfield, Boston, and Brockton. 
 In 2015, the statewide chlamydia incidence rate of 352.0 per 100,000 population was lower 
than the national rate of 478.8 per 100,000.
2
  
 Massachusetts ranked ninth lowest in chlamydia incidence among the 50 states. 2   
 
  
                                                 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015. Atlanta: U.S. Department of 
Health and Human Services; 2016 
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CHLAMYDIA 
 
 
 The chlamydia incidence rate remained highest among adolescents and young adults.  
 In 2015, the chlamydia incidence rate among young adults (ages 20–24) was nearly six times 
higher than the statewide rate in all ages (1,933.0 compared to 352.0 per 100,000).  
 The rate among adolescents (ages 15–19) was over three times higher than the statewide rate 
in all ages (1,150.1 compared to 352.0 per 100,000). 
 
Additional information about chlamydia and other STDs is available online at 
www.mass.gov/dph/cdc/std. 
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GONORRHEA 
 
 3,688 gonorrhea cases were reported in 2015.  
 The total number of reported gonorrhea cases increased by 52% from 2,428 in 2006 to 3,688 
in 2015.  
 Between 2006 and 2015, the gonorrhea incidence rate reported among men doubled (from 
39.5 per 100,000 to 81.3 per 100,000). The gonorrhea incidence rate among men is now 
nearly three times higher than the rate among women (28.8 per 100,000).  
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 Incident gonorrhea was clustered in urban areas in 2015. 
 The five cities with the highest rates were Provincetown, Boston, Brockton, Cambridge, and 
Somerville. 
 The statewide incidence rate of 54.3 per 100,000 was about half the national rate of 123.9 per 
100,000.
2
  
 Massachusetts ranked ninth lowest in gonorrhea incidence rate among the 50 states.2 
 
 
 
 
 
 
 
 
 
 
 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015. Atlanta: U.S. Department of 
Health and Human Services; 2016  
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GONORRHEA 
 
 The gonorrhea incidence rate remained highest among young adults.  
 In 2015, the gonorrhea incidence rate among young adults (ages 20–24) was four times the 
statewide incidence rate in all ages (211.9 compared to 54.3 per 100,000). 
 The rate among young adults (ages 25–29) was three times higher than the statewide rate in 
all ages (178.2 compared to 54.3 per 100,000).  
  
Additional information about gonorrhea and other STDs is available online at 
www.mass.gov/dph/cdc/std. 
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SYPHILIS  
 
 792 infectious syphilis (primary, secondary, and early latent) cases were reported in 2015. 
 The total number of reported infectious syphilis cases in 2015 (N=792) was nearly four times 
the number reported in 2006 (N=219). 
 Between 2006 and 2015, the syphilis incidence rate reported among men more than tripled 
(from 6.4 to 22.4 per 100,000). The syphilis incidence rate among men is now 14 times 
higher than the rate among women (1.6 per 100,000).  
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 The highest syphilis incidence rates were in Suffolk (40.0 per 100,000) and Hampden (17.0 
per 100,000) counties.   
 The statewide infectious syphilis incidence rate increased from 3.4 per 100,000 in 2006 to a 
ten-year high of 11.7 per 100,000 in 2015. Massachusetts ranked 17th in primary and 
secondary syphilis incidence rate among the 50 states.
2
 
 
 
 
 
 
 
 
 
 
 
 
2 Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015. Atlanta: U.S. Department of 
Health and Human Services; 2016  
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SYPHILIS 
 
 
 In 2015, the infectious syphilis rate was highest among individuals aged 20 to 24 years, 
closely followed by individuals 25 to 29 years, and 30 to 39 years. 
 In 2015, the infectious syphilis incidence rates among individuals aged 20 to 24 years, 25 to 
29 years, and 30 to 39 years were all approximately double the overall statewide incidence 
rate in all ages (28.3, 25.7, and 24.5, respectively, compared to 11.7 per 100,000).   
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 In 2015, the infectious syphilis incidence rate was four times higher in the Hispanic/Latino 
population (28.7 cases per 100,000) and three times higher in the black (non-Hispanic) 
population (23.1 cases per 100,000) compared to the white (non-Hispanic) population (7.8 
cases per 100,000).   
Additional information about infectious syphilis is available online at 
www.mass.gov/dph/cdc/std. 
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HIV/AIDS  
 
 
 The number of people known to be living with HIV infection in Massachusetts increased by 
26% from 15,666 on December 31, 2005 to 19,747 on December 31, 2014.  
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 In 2014, there were 629 HIV infections diagnosed and 231 deaths among people reported 
with HIV infection in Massachusetts.  
 The number of HIV infection diagnoses decreased by 31% from 2005 (N=913) to 2014 
(N=629).  
 The number of deaths among people reported with HIV/AIDS also decreased by 31% from 
333 in 2005 to a new low of 231 deaths in 2014.  
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 Of the 351 cities and towns in Massachusetts, 195 (56%) had at least one reported HIV 
infection diagnosis from 2012 to 2014.   
 The majority of HIV infection diagnoses were reported in people living in large urban areas.  
 Of those cities and towns where HIV infections were diagnosed within the three-year period 
2012 to 2014, the majority (77%) had rates under ten per 100,000 population.  
 Provincetown was the only locality with a rate of over 100 per 100,000 during this time 
period. 
 Other areas of higher incidence rates were clustered in and around major cities such as 
Boston, Worcester, and Springfield.   
 
2015 Integrated HIV/AIDS, STD, and Viral Hepatitis Surveillance Report 
Massachusetts Department of Public Health 
 
  - 16 - 
 
 
HIV/AIDS 
 
 
 From 2012 to 2014, of the 2,027 HIV infections newly diagnosed in Massachusetts, 1,510 
(74%) were in men and 517 (26%) were in women.   
 Among men, the largest proportion of newly diagnosed HIV infections were in white (non-
Hispanic) men, whereas among women the majority of newly diagnosed HIV infections were 
in black (non-Hispanic) women. 
 With age-adjusted average annual rates of HIV diagnosis during 2012 to 2014 of 48.5 and 
31.3 cases per 100,000 population, black (non-Hispanic) and Hispanic/Latino individuals 
were diagnosed at rates 10 and 7 times that of white (non-Hispanic) individuals (4.8 per 
100,000), respectively.  
o Among women, the level of disparity was more pronounced: the age-adjusted average 
annual rate of HIV diagnosis during 2012 to 2014 among black (non-Hispanic) 
women (40.9 per 100,000) was 33 times, and among Hispanic/Latina women (15.2 
per 100,000) was 12 times that of white (non-Hispanic) women (1.2 per 100,000).  
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 From 2012 to 2014, the primary risk reported for newly diagnosed HIV infection in 
Massachusetts was male-to-male sex (45%). A significant proportion of diagnoses were 
reported with No Identified Risk (25%).
3
 
 
 
  
                                                 
3
 The category of presumed heterosexual is used exclusively for women, to define HIV exposure mode in cases 
when sex with men is the only reported risk factor for HIV infection. 
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 Since the mid-1990’s, Massachusetts has experienced a dramatic reduction in mother-to-
child transmission of HIV infection due to high rates of antiretroviral treatment in HIV+ 
women, and progresss in HIV screening during pregnancy.  
 From 2005 to 2014, the number of HIV-infected newborns remained between zero and five 
cases annually, with two cases identified in 2014.   
Additional information about HIV/AIDS is available online through the MDPH HIV/AIDS 
Epidemiologic Profile at  www.mass.gov/dph/cdc/aids. 
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VIRAL HEPATITIS – HEPATITIS B 
 
 In 2015, 471 confirmed chronic hepatitis B virus (HBV) cases were reported. An additional 
1,380 probable HBV cases were reported for a total of 1,851 confirmed and probable HBV 
cases. 
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 The incidence rate of confirmed and probable chronic HBV cases among men decreased 
from 37.3 per 100,000 in 2007 to 31.4 per 100,000 in 2015. The chronic HBV incidence rate 
among women decreased from 27.7 per 100,000 in 2007 to 22.9 per 100,000 in 2015. 
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 In 2015, there were 26 confirmed acute and 93 suspect acute HBV cases for a total of 119 
acute cases.   
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VIRAL HEPATITIS - HEPATITIS C 
 
 
 The annual number of confirmed and probable hepatitis C cases reported in Massachusetts 
since 2007 remained high with about 8,000 to 9,000 probable and confirmed cases reported 
each year.   
 There were 5,845 confirmed and 3,267 probable hepatitis C cases reported to MDPH in 
2015, for a total of 9,112.   
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VIRAL HEPATITIS - HEPATITIS C 
 
 
 
 In 2007, reported cases of hepatitis C were distributed in a curve with two age peaks, with 
the lower peak at age 28 years and the higher peak at age 49 years.  
 In 2015, the reported cases were again distributed in a bi-modal curve, but with the higher 
peak at age 25 years and the lower peak at age 57 years. 
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 Fifty-three percent of confirmed and probable hepatitis C cases less than 30 years of age 
were men, and 47% were women. 
 The majority of new hepatitis C infections in persons less than 30 years of age were 
attributable to blood exposure in the context of injection drug use. 
 Sixty percent of confirmed and probable hepatitis C cases 30 years of age and older were 
men, and 40% were women. 
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Strengths and Limitations of Data 
 
  
HIV/AIDS Case Data 
 
STD Case Data 
 
Viral Hepatitis Case Data 
Description 
 
 Collected by MDPH Bureau of Infectious Disease and Laboratory Sciences 
 Reportable statewide. 
 All laboratories and healthcare providers are required by law to report.  
 Includes individuals first 
diagnosed with HIV 
infection in MA. 
 Includes individuals first 
reported as living in MA. 
 Includes individuals first 
reported as living in MA. 
Strengths  Completeness of 
race/ethnicity data is high. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
 Data are estimated to be 
99% complete. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
 Most infectious syphilis 
cases agree to interview, 
resulting in reasonably 
complete race/ethnicity 
and sex of sex partner 
data. 
 All clinical laboratories in 
MA report electronically 
resulting in more complete 
and timely reporting of 
disease. 
Limitations  Due to extensive follow 
up conducted to verify 
accurate date of diagnosis, 
annual incidence data are 
released a year after the 
close of the year. For 
example, 2016 HIV 
diagnoses through 
December 31, 2016 will 
be released on January 1, 
2018. 
 Race/ethnicity data are 
incomplete for gonorrhea 
and chlamydia cases. 
 Sex of sex partner is not 
routinely collected for 
gonorrhea and chlamydia 
cases. 
 Bias is introduced for 
some STDs, such as 
chlamydia infection, 
where screening of 
asymptomatic persons 
occurs more frequently in 
women than in men. 
 Race/ethnicity data are 
incomplete. 
 Risk history data are not 
collected on chronic HBV 
cases. 
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Interpreting HIV/AIDS, STD, and Viral Hepatitis Data 
Hepatitis B surveillance data reported are current as of August 17, 2016, hepatitis C data are as 
of August 19, 2016, HIV/AIDS data are as of March 1, 2016 and STD data are as of October 4, 
2016. All data are subject to change. 
I.  HIV/AIDS Exposure Mode Definitions 
The HIV/AIDS exposure mode indicates the most probable risk behavior associated with HIV 
infection.  Assignment of exposure mode is done in accordance with Centers for Disease Control and 
Prevention (CDC) guidelines when multiple exposure modes are reported.  Following is a description 
of the exposure mode categories: 
 MSM (Male to Male Sex):  Includes males who report sexual contact with other 
males, and males who report sexual contact with both males and females. Please note the 
acronym MSM is also used to refer to “men who have sex with men”. 
 IDU (Injection Drug Use):  Cases in persons who report injection drug use. 
 MSM/IDU:  Cases in males who report both injection drug use and sexual contact with 
other males. 
 Heterosexual Sex:  Cases in persons who report specific heterosexual sex with a person   
with, or at increased risk for, HIV infection (e.g. an injection drug user).  The sub-categories 
for this mode of transmission are listed below. 
o Heterosexual Sex w/ an Injection Drug User 
o Heterosexual Sex w/ a person w/ HIV infection or AIDS 
o Heterosexual Sex w/ Bisexual male 
o Other Heterosexual Sex:  Includes all other sub-categories of risk, such as heterosexual 
contact with a person infected through a blood transfusion. 
 Presumed Heterosexual:  Cases among females who report heterosexual sex but do 
not report any other personal risk or any knowledge of specific risk in their male sex 
partners.  As of January 1, 2011, males who were previously grouped in this 
category are categorized as No Identified Risk.  Presumed heterosexual is an exposure 
mode category used by the Massachusetts HIV/AIDS Surveillance Program.  The CDC 
categorizes these cases as No Identified Risk. 
 Pediatric:  Infection before the age of 13 years, including mother to child transmission 
through pregnancy, childbirth or breastfeeding and blood transfusions to children. 
 NIR (No Identified Risk):  Cases in persons with no reported history of exposure to HIV 
through any of the listed exposure categories.  Follow-up is conducted to determine risk for those 
cases that are initially reported without a risk identified.  Includes cases among males who 
were previously categorized in Massachusetts as Presumed Heterosexual. 
 
II.  References to Newly Diagnosed HIV Infections 
Due to the extensive follow up required to verify accurate date of diagnosis, all HIV/AIDS data 
reflect HIV infections diagnosed through 2014.  Newly diagnosed HIV infections/cases include 
all persons diagnosed with HIV from 2012 to 2014, including those who were concurrently or 
subsequently diagnosed with AIDS. All HIV data are presented by the year of diagnosis, not the 
year of report. 
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III.  Race/Ethnicity of STD and HIV/AIDS Cases 
Race/ethnicity references to white residents and black residents represent persons who are white non-
Hispanic and black non-Hispanic, respectively.  All references to Hispanic/Latino for race/ethnicity 
represent persons of Hispanic/Latino heritage regardless of race.  
IV.  STD Case Reports and Analyses 
All information on STD cases reflect year of report and all incidence calculations represent crude 
rates. The source of denominators for calculating rate trends was: Intercensal Estimates of the 
Resident Population by Sex and Age for Massachusetts: April 1, 2000 to July 1, 2010 (ST-
EST00INT-02-25); Source: U.S. Census Bureau, Population Division; Release Date: October 
2012 and Estimates of the Resident Population by Sex, Race, and Hispanic Origin for the United 
States, States, and Counties: April 1, 2010 to July 1, 2015, Source: U.S. Census Bureau, 
Population Division; Release Date: June 2016.  The source of denominators for calculating rate 
maps was the 2010 US Census. The distribution of STD cases in incidence rate calculations with 
unknown values for race/ethnicity has changed compared to previous reports.  Cases with 
unknown values are now redistributed proportionally based on the distribution of cases with 
known values. Due to this change, STD incidence rates by race/ethnicity are slightly higher for 
all years than previously reported.  
 
V. Cell suppression methodology: 
Values less than five are suppressed for denominator populations less than 50,000 or for 
unknown values. Additional values may be suppressed to prevent back calculation. 
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HIV/AIDS, STD, and Viral Hepatitis Case Classifications (in the time period 
of the data in this report) 
HIV INFECTION 
 
Clinical description: HIV (human immunodeficiency virus) is a retrovirus with two serologically 
and geographically distinct species: HIV-1 and HIV-2. It is spread via person-to-person 
transmission through: sexual contact, the use of HIV-contaminated needles and syringes, vertical 
transmission from mother to infant, or the transfusion of contaminated blood or its components. 
HIV attacks the body’s immune system, making the person more likely to get infections or 
infection-related cancers. These opportunistic infections or cancers take advantage of the 
weakened immune system and signal that the person has AIDS (acquired immunodeficiency 
syndrome), the advanced stage of HIV infection. 
 
Case Classification 
Confirmed: Positive HIV-1, Positive HIV-2, or Positive (Undifferentiated) HIV result from a 
differentiating immunoassay, Western Blot, IFA, or culture; Positive/Detected Qualitative HIV 
NAT (DNA or RNA); Quantitative HIV NAT (detectable viral load assay) or physician verified 
diagnosis. 
 
 
STD 
 
Chlamydia trachomatis, Infection (Revised 6/09)  
 
Clinical description:  Infection with Chlamydia trachomatis may result in urethritis, 
epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted; 
however, the infection is often asymptomatic in women. Perinatal infections may result in 
inclusion conjunctivitis and pneumonia in newborns. Other syndromes caused by C. trachomatis 
include lymphogranuloma venereum (see Lymphogranuloma Venereum) and trachoma.  
 
Laboratory criteria for diagnosis 
• Isolation of C. trachomatis by culture or  
• Demonstration of C. trachomatis in a clinical specimen by detection of antigen or nucleic acid  
 
Case classification  
 
Confirmed: a case that is laboratory confirmed  
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Gonorrhea (effective January 1, 2014)  
 
Clinical description: A sexually transmitted infection commonly manifested by urethritis, 
cervicitis, proctitis, salpingitis, or pharyngitis. Infection may be asymptomatic.  
 
Laboratory Criteria for Diagnosis  
• Observation of gram-negative intracellular diplococci in a urethral smear obtained from a male 
or an endocervical smear obtained from a female, or  
• Isolation of typical gram-negative, oxidase-positive diplococci by culture (presumptive 
Neisseria gonorrhoeae) from a clinical specimen, or  
• Demonstration of N. gonorrhoeae in a clinical specimen by detection of antigen or nucleic acid  
 
Case Classification  
Probable: demonstration of gram-negative intracellular diplococci in a urethral smear obtained 
from a male or an endocervical smear obtained from a female. 
Confirmed: a person with laboratory isolation of typical gram-negative, oxidase-positive 
diplococci by culture (presumptive Neisseria gonorrhoeae) from a clinical specimen, or 
demonstration of N. gonorrhoeae in a clinical specimen by detection of antigen or detection of 
nucleic acid via nucleic acid amplification (e.g., PCR) or hybridization with a nucleic acid probe.  
 
Syphilis (effective Jan 1, 2014)  
 
Syphilis is a complex sexually transmitted infection that has a highly variable clinical course. 
Adherence to the following surveillance case definitions will facilitate understanding the 
epidemiology of this disease across the U.S.  
 
Syphilis, primary  
 
Clinical description: A stage of infection with Treponema pallidum characterized by one or more 
ulcerative lesions (e.g. chancre), which might differ considerably in clinical appearance.  
 
Laboratory criteria for diagnosis:  
Demonstration of T. pallidum in clinical specimens by darkfield microscopy, or by polymerase 
chain reaction (PCR) or equivalent direct molecular methods.  
 
Case classification  
 
Probable: a case that meets the clinical description of primary syphilis with a reactive serologic 
test (nontreponemal: Venereal Disease Research Laboratory [VDRL], rapid plasma reagin 
[RPR], or equivalent serologic methods; treponemal: fluorescent treponemal antibody absorbed 
[FTA-ABS], T. pallidum particle agglutination [TP-PA], enzyme immunoassay [EIA], 
chemiluminescence immunoassay [CIA], or equivalent serologic methods).
4
 
 
                                                 
4
 These treponemal tests supersede older testing technologies, including microhemagglutination assay for antibody 
to T. pallidum [MHA-TP]. 
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Confirmed: a case that meets the clinical description of primary syphilis that is laboratory 
confirmed  
 
Syphilis, secondary  
 
Clinical description: A stage of infection caused by T. pallidum characterized by localized or 
diffuse mucocutaneous lesions (e.g., rash — such as non-pruritic macular, maculopapular, 
papular, or pustular lesions), often with generalized lymphadenopathy. Other symptoms can 
include mucous patches, condyloma lata, and alopecia. The primary ulcerative lesion may still be 
present. Because of the wide array of symptoms possibly indicating secondary syphilis, serologic 
tests for syphilis and a thorough sexual history and physical examination are crucial to 
determining if a case should be classified as secondary syphilis.  
 
Laboratory criteria for diagnosis:  
• Demonstration of T. pallidum in clinical specimens by darkfield microscopy, or by polymerase 
chain reaction (PCR) or equivalent direct molecular methods  
 
Case classification  
 
Probable: a case that meets the clinical description of secondary syphilis with a nontreponemal 
(VDRL, RPR, or equivalent serologic methods) titer ≥4 AND a reactive treponemal test (FTA-
ABS, TP-PA, EIA, CIA, or equivalent serologic methods.  
 
Confirmed: a case that meets the clinical description of secondary syphilis (with at least one sign 
or symptom) that is laboratory confirmed. 
 
Syphilis, early latent  
 
Clinical description: A subcategory of latent syphilis (a stage of infection caused by T. pallidum 
in which organisms persist in the body of the infected person without causing symptoms or 
signs) when initial infection has occurred within the previous 12 months.  
 
Case classification  
 
Probable:  A person with no clinical signs or symptoms of syphilis who has one of the following:  
 
No past diagnosis of syphilis, AND a reactive nontreponemal test (e.g., VDRL, RPR, or 
equivalent serologic methods), AND a reactive treponemal test (e.g., FTA-ABS, TP-PA, EIA, 
CIA, or equivalent serologic methods),  
 
OR  
 
A current nontreponemal test titer demonstrating fourfold or greater increase from the last 
nontreponemal test titer.  
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AND  
 
Evidence of having acquired the infection within the previous 12 months based on one or more 
of the following criteria:  
• Documented seroconversion or fourfold or greater increase in titer of a nontreponemal test 
during the previous 12 months  
• Documented seroconversion of a treponemal test during the previous 12 months  
• A history of symptoms consistent with primary or secondary syphilis during the previous 12 
months  
• A history of sexual exposure to a partner within the previous 12 months who had primary, 
secondary, or early latent syphilis (documented independently as duration < 12 months)  
• Only sexual contact was within the last 12 months (sexual debut)  
 
There is no confirmed case classification for early latent syphilis.  
 
Viral Hepatitis 
 
Hepatitis is inflammation of the liver. It can impair vital liver functions such as processing 
nutrients, filtering the blood and fighting infection. Viral hepatitis is inflammation of the liver 
caused by infection with a virus. In Massachusetts, the most common types of viral hepatitis are 
hepatitis A, hepatitis B and hepatitis C. Hepatitis can also result from heavy alcohol use, toxins, 
some medications, and certain medical conditions.  
 
Chronic HBV 
Confirmed: 
 
IgM antibodies to hepatitis B core antigen (IgM anti-HBc) negative  
 
AND  
 
A positive result on one of the following tests: hepatitis B surface antigen (HBsAg), 
hepatitis B e antigen (HBeAg), or nucleic acid test for hepatitis B virus DNA 
(including qualitative, quantitative and genotype testing),  
 
OR 
 
HBsAg positive or nucleic acid test for hepatitis B virus DNA (including qualitative, 
quantitative and genotype testing), or HBeAg positive two times at least 6 months apart 
(Any combination of these tests performed 6 months apart is acceptable.) 
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Probable: 
A case with a single HBsAg positive or HBV DNA positive (including qualitative, quantitative 
and genotype testing), or HBeAg positive lab result when no IgM anti-HBc results are available 
 
Acute HBV infection 
Clinical Presentation: An acute illness with a discrete onset of symptoms consistent with acute 
viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and 
abdominal pain) and either a) jaundice or b) elevated serum alanine aminotransferase levels > 
100 IU/L 
 
Confirmed: 
Clinically compatible case* not known to have chronic hepatitis B and 
HBsAg positive  
 
AND 
 
IgM antibody to hepatitis B core antigen (IgM anti– HBc) positive, if done *  
 
A documented negative hepatitis B surface antigen (HBsAg) laboratory test result within 6 
months prior to a positive test (either HBsAg, Hepatitis B “e” antigen (HBeAg), or hepatitis 
B virus nucleic acid testing (HBV NAT) including genotype) result does NOT require an 
acute clinical presentation to meet the surveillance case definition. 
 
Suspect: 
Positive IgM antibody to hepatitis B core antigen (IgM anti-HBc) that does not meet the clinical 
definition 
 
Note that the year into which a case is categorized is based upon the case’s “Event Date”, which 
is assigned by the following case characteristics, in decreasing order of specificity, dependent on 
availability of information: symptom onset date, specimen collection date, diagnosis date, or case 
report date 
 
Past or Present HCV Infection Newly Reported to MDPH 
Confirmed: 
One or more of the following criteria (except in persons less than 18 months of age, for whom 
only criteria 3 would meet the case classification criteria): 
 
Antibodies to hepatitis C virus (anti-HCV) screening-test-positive with a signal to cut-off ratio 
predictive of a true positive as determined for the particular assay as defined by CDC 
 
OR 
 
Hepatitis C Virus Recombinant Immunoblot Assay (HCV RIBA) positive 
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OR 
 
Nucleic Acid Test (NAT) for HCV RNA positive (including qualitative, quantitative, or 
genotype) 
 
Probable: 
 
Rapid HCV antibody positive test 
 
OR 
 
Anti-HCV screening-test-positive that has not been verified by a more specif ic  assay or has 
unknown signal to cut-off ratio (regardless of ALT results and acute hepatitis C status) 
 
Acute HCV Infection 
Confirmed: 
Clinically compatible presentation* not known to have chronic HCV with 1 or more of the 
following: 
 
Anti-HCV screening-test-positive with a signal to cut-off ratio predictive of a true positive as 
determined for the particular assay as defined by CDC 
 
OR 
 
HCV RIBA positive 
 
OR 
 
NAT for HCV RNA positive (including qualitative, quantitative, or genotype) 
 
AND 
 if done meets the following two criteria†: 
 
IgM anti-HAV negative AND 
IgM anti-HBV negative 
 
* - A documented negative HCV antibody laboratory result followed within 6 months by 
a positive test result (as described above) does NOT require an acute clinical 
presentation to meet the confirmed case definition 
 
† - From 2007-2013, cases meeting the acute case definition but missing a negative 
HAV & HBV result were classified as Suspect. The case definition change in 2013 
eliminated this requirement. 
 
Suspect: 
 
A documented negative HCV antibody laboratory test result followed within 6-12 
months by a positive test result (as described   above) does NOT require an acute clinical 
presentation to meet the suspect case definition. 
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Low level viremia (<100,000 IU/mL) not known to have chronic HCV 
 
Note that the year into which a case is categorized is based upon the case’s “Event 
Date”, which is assigned by the following case characteristics, in decreasing order of 
specificity, dependent on availability of information: symptom onset date, specimen 
collection date, diagnosis date, or case report date. 
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HIV/AIDS, STD and Viral Hepatitis Program Staff Contact Information 
 
Topic Contact E-Mail Phone 
 
Division of STD Prevention & HIV/AIDS Surveillance, and 
Ratelle STD/HIV Prevention Training Center 
Policy Development and 
Administration 
Kathleen Roosevelt (Director, STD 
Prevention Division) 
Kathleen.roosevelt@state.ma.us 617-983-6941 
Sylvie Ratelle STD/HIV 
Prevention Training Center 
Katherine Hsu (Medical Director) 
Janine Dyer (Deputy Director) 
Katherine.Hsu@state.ma.us 
Janine.Dyer@state.ma.us 
617-983-6948 
617-983-6964 
STD/HIV/AIDS 
Surveillance and 
Epidemiology 
Betsey John (Director, HIV/AIDS and 
STD Surveillance) 
 
Betsey.John@state.ma.us 
 
 
617-983-6570 
 
STD Clinical Services  Katherine Hsu (Medical Director) 
Barbara Coughlin (Public Health Nurse) 
Katherine.Hsu@state.ma.us 
Barbara.Coughlin@state.ma.us 
617-983-6948 
413-586-7525 
STD Disease Intervention 
Field Services and  
STD Partner Notification 
David Goudreau 
(Field Operations Manager) 
Christopher Borger 
(Field Operations Manager) 
David.Goudreau@state.ma.us 
 
Chris.Borger@state.ma.us   
617-983-6835 
 
617-983-6930 
STD Health Education, 
Training, and Prevention 
Brenda Hernandez 
(Special Projects Coordinator) 
  
Brenda.Hernandez@state.ma.us 
 
 
617-983-6943 
 
 
Office of HIV/AIDS 
HIV/AIDS Resource 
Allocation, Policy, and  
Programs  
Dawn Fukuda (Director, Office of 
HIV/AIDS) 
 
Dawn.Fukuda@state.ma.us 
 
 
617-624-5303 
 
 
Health Promotion and 
Disease Prevention 
Services 
 
Linda Goldman, (Director of Health 
Promotion and Disease Prevention)  
 
Linda.Goldman@state.ma.us 
 
617-624-5347 
 
Behavioral Health and 
Community Engagement  
 
Barry Callis  
(Director of Behavioral Health and 
Infectious Disease Prevention 
 
Barry.Callis@state.ma.us 
 
617-624-5316 
 
Viral Hepatitis Program 
Viral Hepatitis 
Surveillance and 
Epidemiology 
Shauna Onofrey (Viral Hepatitis 
Surveillance Coordinator) 
 
Susan Soliva (Epidemiologist) 
Shauna.Onofrey@state.ma.us 
 
 
Susan.Soliva@state.ma.us 
617-983-6776 
 
 
617-983-6883 
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HIV/AIDS, STD, and Viral Hepatitis Resources 
 
Training 
Professional training to community based organizations, local public health departments, and medical providers can 
be requested and is free of charge.  
Type of Training Contact Information and Website 
STD Education, STD Partner Notification, and  
STD Reporting  
617-983-6940 
www.mass.gov/dph/cdc/std 
HIV/AIDS Reporting and Surveillance Projects 
617-983-6560 
www.mass.gov/dph/cdc/aids 
HIV/AIDS Provider Trainings 
617-624-5338 
 www.mass.gov/dph/aids  
Viral Hepatitis Education 
617-983-6800 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id
/epidemiology/hepatitis/hepatitis-c/viral-hepatitis-educational-
materials.html  
STD Diagnosis, Treatment, and Management 
617-983-6945 
www.RatellePTC.org 
Material and Clinical Toolkits  
Health education materials and clinical toolkits can be requested free of charge.  
Type of Material Contact Information and Website 
STD, HIV, Viral Hepatitis Fact Sheets  
617-983-6940 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id/e
pidemiology/factsheets.html#std  
HIV/AIDS Reporting for Health Care Providers 
Brochure 
617-983-6560 
http://www.mass.gov/eohhs/gov/departments/dph/programs/id/h
iv-aids/reporting/  
STD, and HIV Posters and Brochures 
617-983-6800 
https://massclearinghouse.ehs.state.ma.us/  
STD Diagnosis, Treatment, and  
Management Toolkits 
617-983-9645 
www.RatellePTC.org 
  
MDPH and MDPH Funded Websites  
Division of STD Prevention   www.mass.gov/dph/cdc/std 
HIV/AIDS Bureau    www.mass.gov/dph/aids 
HIV/AIDS Surveillance    www.mass.gov/dph/cdc/aids 
Viral Hepatitis Program    www.mass.gov/hepc 
Sylvie Ratelle STD/HIV Prevention Training Center www.RatellePTC.org 
National Websites  
Center for Disease Control and Prevention  www.cdc.gov 
Division of STD Prevention  www.cdc.gov/std 
Division of HIV/AIDS Prevention  www.cdc.gov/hiv 
Division of Viral Hepatitis   www.cdc.gov/hepatitis 
National Network of STD/HIV Prevention  
Training Centers     www.nnptc.org 
CDC funded viral hepatitis online training  http://depts.washington.edu/hepstudy/  
 
